Neoleukin Therapeutics (NASDAQ:NLTX) Trading Down 1.2%

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)’s share price was down 1.2% during mid-day trading on Thursday . The stock traded as low as $28.09 and last traded at $29.87. Approximately 71,109 shares were traded during mid-day trading, an increase of 42% from the average daily volume of 50,104 shares. The stock had previously closed at $30.23.

Neoleukin Therapeutics Stock Up 0.3 %

The firm has a market capitalization of $281.56 million, a PE ratio of -9.63 and a beta of 1.11. The firm’s fifty day simple moving average is $37.24 and its 200-day simple moving average is $25.62.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Neoleukin Therapeutics stock. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 310,000 shares of the company’s stock, valued at approximately $1,224,000. Adage Capital Partners GP L.L.C. owned about 3.52% of Neoleukin Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 52.37% of the company’s stock.

About Neoleukin Therapeutics

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.